Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction: Use of natural supplements to improve mitochondrial function

Functional Foods in Health and Disease

Volumn 4, Issue 1, 2014, Pages 23-65

  Nicolson, Garth L ^a   Settineri, Robert ^b   Ellithorpe, Rita R ^c  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b Sierra Productions Research LLC   (United States)

^c Tustin Longevity Center   (United States)

Author keywords

ATP; Infections and mitochondrial dysfunction; Lipid Replacement Therapy (LRT); Neurodegenerative and fatiguing illnesses

Indexed keywords

EID: 84932627130     PISSN: 23787007     EISSN: 21603855     Source Type: Journal    
DOI: 10.31989/ffhd.v4i1.26     Document Type: Review

References (321)

1. Nicolson GL. Chronic infections in neurodegenerative and neurobehavioral diseases. Lab Med 2008; 39(5): 291-299.
2. Nicolson GL, Haier J. Role of chronic bacterial and viral Infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune and fatiguing illnesses: Part 1. Brit J Med Practit 2009; 2(4): 20-28.
3. Nicolson GL, Haier J. Role of chronic bacterial and viral Infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune and fatiguing illnesses: Part 2. Brit J Med Practit 2010; 3(1): 301-311.
4. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolec Med 2008; 10(4): 291-315.
5. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011; 8(4): 393-409.
6. Nicolson GL. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Alt Ther Health Med 2013; 19: at5027. [Epub ahead of print].
7. Nicolson GL, Settineri R. Lipid Replacement Therapy: a functional food approach with new formulations for reducing cellular oxidative damage, cancer-associated fatigue and the adverse effects of cancer therapy. Funct Food Health Dis 2011; 1(4): 135-160.
8. De Chiara G, Marococci ME, Sgarbanti R, Civitelli L, Ripoli C, Placentini R, Garaci E, Grassi C, Palamara AT. Infectious agents and neurodegeneration. Mol Neurobiol 2012; 46(3): 614-638.
9. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25(suppl): 74-80.
10. Sherbet G. Bacterial infections and the pathogenesis of autoimmune conditions. Brit J Med Practit 2009; 2(1): 6-13.
11. Nicolson GL, Haier J, Nasralla M, Nicolson NL, Ngwenya R, De Meirleir K. Mycoplasmal infections in Chronic Fatigue Syndrome, Fibromyalgia Syndrome and Gulf War Illness. J Chronic Fatigue Syndr 2000; 6(3): 23-39.
12. Verdon ME, Sigal LH. Recognition and management of Lyme Disease. Am Family Physician 1997; 56: 427-436.
13. Homer MJ, Aguilar-Delfin I, Telford SR 3rd, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev 2000; 13: 451-469.
14. Kizilkilic O, Calli C. Neurobrucellosis. Neuroimaging Clin N Am 2011; 21: 927-937.
15. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Brit J Anaesth 2011; 107: 57-64.
16. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J gastroenterol Hepatol 2004; 16: 1-11.
17. Rusconi B, Greub G. Chlamydiales and the innate immune response: friend or foe? FEMS Immunol Med Microbiol 2011; 61: 231-244.
18. Richter C, Par JW, Ames B. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Nat Acad Sci USA 1998; 85: 6465-6467.
19. Stadtman E. Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Radical Biol Med 2002; 32: 789.
20. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985; 26: 101-105.
21. Nicolson GL. Diagnosis and therapy of chronic systemic co-infections in Lyme Disease and other tick-borne infectious diseases. Townsend Lett 2007; 285: 93-98.
22. Burrascano JJ. Diagnostic hints and treatment guidelines for Lyme and other tick-borne diseases. In: Advanced Topics in Lyme Disease, Managing Lyme Disease, 16th edition, 5-28, 2008.
23. Muravchick S, Levy RJ. Clinical implications of mitochondrial dysfunction. Anesthesiol 2006; 105: 819-837.
24. Keen D, Ward S. Autistic Spectrum Disorder. Autism 2004; 8: 39-58.
25. Fatemi SH, Reutiman TJ, Folsom TD, Sidwell RW. The role of cerebellar genes in pathology of autism and schizophrenia. Cerebellum 2008; 99: 56-70.
26. Nicolson GL, Gan R, Nicolson NL, Haier J. Evidence for Mycoplasma, Chlamydia pneunomiae and HHV-6 co-infections in the blood of patients with Autism Spectrum Disorders. J Neurosci Res 2007; 85: 1143-1148.
27. Bransfield RC. Preventable cases of autism: relationship between chronic infectious diseases and neurological outcome. Pediat Health 2009; 3(2): 125-140.
28. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatr 2004; 113: 72-86.
29. Dhillon VS, Fenech M. Mutations that affect mitochondrial functions and their association with neurodegenerative diseases. Mutat Res 2013; Sept 17 doi: 10.1016/j.mrrev.2013.09.001 [Epub ahead of print].
30. Frye RE, Delatorre R, Taylor H, Slattery J, Melnyk S, Chowdhury N, James SJ. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl Psychiatry 2013; 3: e273 [Epub ahead of print].
31. Deth R, Muratore C, Benzercry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicol 2008; 29: 190-201.
32. Mattson MP. Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 2004; 3: 105-120.
33. Bazala E, Renda J. Latent Chlamydial infections: the probably cause of a wide spectrum of human diseases. Med Hypotheses 2005; 65: 578-584.
34. Williams DB, Windebank AJ. Motor neuron disease (Amyotrophic Lateral Sclerosis). Mayo Clinic Proc 1991; 66: 54-82.
35. Walling AD. Amyotrophic Lateral Sclerosis: Lou Gehrig's Disease. Am Family Physician 1999; 59: 1489-1496.
36. Berger MM, Kopp N, Vital C, Redi B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000; 54: 20-25.
37. Walker MP, Schlaberg R, Hays AP, Bowser R, Lipkin WI. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 2001; 49: 249-253.
38. Nicolson GL, Berns P, Nasralla M, Haier J, Pomfret J. High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). J Clin Neurosci 2002; 9: 525-429.
39. Halperin JJ, Kaplan GP, Brazinsky S, Tsai TF, Cheng T, Ironside A, Wu P, Delfiner J, Golightly M, Brown RH. Immunologic reactivity against Borrelia burgdorferi in patients with motor neuron disease. Arch Neurol 1990; 47: 586-594.
40. Hansel Y, Ackerl M, Stanek G. ALS-like sequelae in chronic neuroborreliosis. Wien Med Wochensch 1995; 147: 186-188.
41. Qureshi M, Bedlack RS, Cudkowicz ME. Lyme disease serology in amyotrophic lateral sclerosis. Muscle Nerve 2009; 40: 626-628.
42. MacDonald AB. Spirochetal cyst forms in neurodegenerative disorders, hiding in plain site. Med Hypotheses 2006; 67: 819-832.
43. Hugan J. ALS therapy: targets for the future. Neurol 1996; 47(suppl 4): S251-S254.
44. McCormick AL, Brown RH Jr, Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurol 2008; 70: 278-283.
45. Stipa G, Taiuti R, de Scisciolo G, Ametoli G, Tredici MR, Biondi N, Barsanti L, Lolli F. Sporadic amyotrophic lateral sclerosis as an infectious disease: a possible role of cyanobacteria? Med Hypotheses 2006; 67: 1363-1371.
46. Cozzolino M, Ferri A, Valle C, Carri MT. Mitochondria and ALS: implications from novel genes and pathways. Mol Cell Neurosci 2013; 55: 44-49.
47. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J, Carr MT. Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antiox Redox Signal 2012; 9: 1277-1330.
48. Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD. Redox regulation in Amyotrophic Lateral Sclerosis. Oxid Med Cell Longev 2013; 2013: 408681. doi: 10.1155/2013/408681.
49. Sobel RA. The pathology of multiple sclerosis. Neurol Clinic 1995; 13: 1-21.
50. Bruck W. Clinical implications of neuropathological findings in multiple sclerosis. J Neurol 2005; 252(suppl 3): 10-14.
51. Muñoz-Culla M, Irizar H, Otaegui D. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet 2013; 8: 63-73.
52. Huynh JL, Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment. Lancet Neurol 2013; 12(2): 195-206.
53. Baranzini SE, Oksenberg JR. Genomics and new targets for multiple sclerosis. Pharmacogenomics 2005; 6: 151-161.
54. Currier RD, Eldridge R. Possible risk factors in multiple sclerosis as found in a national twin study. Arch Neurol 1982; 39: 140-44.
55. Greenlee JE, Rose JW. Controversies in neurological infectious diseases. Semin Neurol 2000; 20: 375-386.
56. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195-202.
57. Malmone D, Gregory S, Arnason BG, et al. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32: 87-74.
58. Woodroofe MN. Cytokine production in the central nervous system. Neurol 1995; 45 (Suppl 6): S6-S10.
59. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurol 1998; 50: 571-572.
60. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
61. Yao S-Y, Stratton CW, Mitchell WM, Sriram S. CFS oligoclonal bands in MS include antibodies against Chamydophila antigens. Neurol 2001; 51: 1168-1176.
62. Contini C, Seraceni S, Castellazzi M, et al. Chlaymdophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis, Neurosci Res 2008; 62: 58-61.
63. Sriram S, Ljunggren-Rose A, Yao S-Y, Whetsell WO Jr. Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis. J Infect Dis 2005; 192: 1219-1228.
64. Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 2004; 10: 360-369.
65. Grimaldi LM, Pincherle A, Martinelli-Boneschi F, Filippi M, Patti F, Reggio A, Franciotta D, Allegra L, Comi G, Blasi F. An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Multiple Sclerosis 2003; 9: 467-471.
66. Dong-Si T, Weber J, Liu YB, Buhmann C, Bauer H, Bendl C, Schnitzier P, Grond-Ginsbach C, Grau AJ. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. J Neurol 2004; 251: 542-547.
67. Stratton CW, Sriram S. Association of Chlamydia pneumoniae with central nervous system disease. Microbes Infect 2003; 5: 1249-1253.
68. Stratton CW, Wheldon DB. Multiple sclerosis: an infectious syndrome in ving Chlamydophia pneumoniae. Trends Microbiol 2006; 14: 474-479.
69. Boman J, Roblin PM, Sundström P, Sundström M, Hmmerschlag MR. Failure to detect Chlamydia pneumoniae in central nervous system of patients with MS. Neurol 2000; 11: 265.
70. Pucci E, Taus C, Cartechini E, Morelli M, Giuliani G, Clementi M, Menzo S. Lack of Chlamydia infection of the central nervous system in multiple sclerosis. Ann Neurol 2000; 48: 399-400.
71. Hammerschlag MR, Ke Z, Lu F, Roblin P, Boman J, Kalman B. Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? J Clin Microbiol 2000; 38: 4274-4276.
72. Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple sclerosis-Are Chlamydia pneumoniae and human herpes virus 6 involved? J Neuroimmunol 2003; 136: 1-8.
73. Nicolson GL. Systemic intracellular bacterial infections (Mycoplasma, Chlamydia, Borrelia species) in neurodegenerative (Alzheimers, MS, ALS) and behavioral diseases (Autistic Spectrum Disorders). Townsend Lett 2008; 295: 74-84.
74. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2: 249-258.
75. Sanders VJ, Felisan S, Waddell A, et al. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2: 249-58.
76. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995; 92: 7440-7444.
77. Sola P, Merelli E, Marasca R, Poggi M, Luppi M, Montorsi M, Torelli G. Human herpesvirus-6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and viral sequences by polymerase chain reaction. J Neurol Neurosurg Psychiat 1993; 56: 917-919.
78. Kuusisto H, Hyöty H, Kares S, Kinnunen E, Elovaara I. Human herpes virus 6 and multiple sclerosis: a Finnish twin study. Mult Scler 2008; 14: 54-58.
79. Steiner I, Nisipianu P, Wirguin I. Infection and etiology and pathogenesis of multiple sclerosis. Curr Neurol Neurosci Rep 2001; 1: 271-76.
80. Giraudon P, Bernard A. Chronic viral infections of the central nervous system: aspects of specific to multiple sclerosis. Rev Neurol (Paris) 2009; 169: 789-795.
81. Frykholm BO. On the question of infectious aetiologies for multiple sclerosis, schizophrenia and the chronic fatigue syndrome and the treatment with antibiotics. Med Hypotheses 2009; 72: 736-739.
82. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013; Jun 2. doi: 10.1016/j.jns.2013.05.010.
83. Campbell GR, Ohno N, Turnbull DM, Mahad DJ. Mitochondrial changes within axons in multiple sclerosis: an update. Curr Opin Nuerol 2012; 4: 169. doi: 10.1097/WCO. 0b013e3283533a25.
84. Su K, Bourdette D, Forte M. Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front Physiol 2013; 4: 169. doi: 10.3389/fphys.2013.00169.
85. Broadwater L, Pandit A, Clements R, Azzam S, Vadnal J, Sulak M, Yong VW, Freeman EJ, Gregory RB, McDonough J, Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys Acta 2011; 1812: 630-641.
86. Su K, Bourdette D, Fore M. Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front Physiol 2013; July 25 doi: 10.3389/fphys.2013.00169.
87. Nicholls DG. Mitochondrial ion circuits. Essays Biochem 2010; 47: 25-35.
88. Mahad D, Lassmann H, Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008; 34: 577-589.
89. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 2006; 129: 2823-2839.
90. Drachman DA. Aging of the brain, entropy, and Alzheimer Disease. Neurol 2006; 67: 1340-1352.
91. Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA and RNA in mild cognitive impairment. Arch Neurol 2007; 64: 954-956.
92. Daly MP. Diagnosis and management of Alzheimer Disease. J Am Board Family Pract 1999; 12: 375-385.
93. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1-beta and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiat 2003; 74: 788-789.
94. Balin BJ, Appelt DM. Role of infection in Alzheimer's Disease. J Am Osteopath Assoc 2001; 101(suppl 12): S1-S6.
95. Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol 2001; 14: 355-359.
96. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan JP, Abrams JT, Whittum-Hudson JA, Hudson AP. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol 1998; 187: 23-42.
97. Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH 2nd, Bordayo EZ, Whittum-Hudson JA, Hudson AP. Chlamydophila (Chlamydia) penumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol 2006; 48: 355-366.
98. MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, Appelt DM, Balin BJ. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res 2003; 71: 740-750.
99. Dreses-Werringloer U, Bhuiyan M, Zhao Y, Gérard HC, Whittum-Hudson JA, Hudson AP. Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. Intern J Med Microbiol 2998; 299: 187-201.
100. Hammond CJ, Hallock LR, Howanski RJ, Appelt DM, Balin BJ. Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. BMC Neurosci 2010; 11: 121. doi: 10.1186.1471-2202-11-121.
101. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 2004; 25: 419-429.
102. Gieffers J, Reusche E, Solbach W, Maass M. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's Disease patients. J Clin Microbiol 2000; 38: 881-882.
103. Meer-Scherrer L, Chang-Loa C, Adelson ME, Mordechai E, Lobrinus JA, Fallon BA, Tilton RC. Lyme disease associated with Alzheimer's Disease. Curr Microbiol 2006; 52: 330-332.
104. Miklossy J, Khalili K, Gern L, Eircson RL, Darekar P, Bolle L, Hurlimann J, Paster BJ. Borrelia burgdorferi persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimer's disease. J Alzheimers Dis 2004; 6: 639-649.
105. MacDonald AB. Alzheimer's Disease Braak Stage progressions: reexamined and redefined as Borrelia infection transmission through neural circuits. Med Hypotheses 2007; 68: 1059-1064.
106. MacDonald AB. Plaques of Alzheimer's Disease originate from cysts of Borrelia burgdorferi, the Lyme Disease spirochete. Med Hypotheses 2006; 67: 592-600.
107. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R, Reiss K, Darbinian N, Darekar P, Mihaly L, Khalili K. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging 2006; 27: 228-236.
108. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's Disease. J Molec Neurosci 2001; 17: 137-145.
109. Marques AR, Weir SC, Fahle GA, Fischer SH. Lack of evidence of Borrelia involvement in Alzheimer's Disease. J Infect Dis 2000; 182: 1006-1007.
110. Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease-role of spirochetes. J Alzheimers Dis 2008; 13: 381-391.
111. Miklossy J. Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med 2011; 13: e30. doi: 10.1017/S1462399411002006.
112. Kountouras J, Boziki JM, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, Tsolaki M, Chatzopoulos D, Katsinelos P, Tzilves D, Zabouri A, Michailidou I. Increased cerebrospinal fluid Helicobacter pylori antibiody in Alzheimer's disease. Intern J Neurosci 2009; 119: 765-767.
113. Robinson SR, Dobson C, Lyons J. Challenges and directions for the pathogen hypothesis of Alzheimer's disease. Neurobiol Aging 2004; 25: 629-637.
114. Denaro FJ, Staub P, Colmer J, Freed DM. Coexistance of Alzheimer's disease neuropathology with herpes simplex encephalitis. Cell Molec Biol 2003; 49: 1233-1240.
115. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimers's disease: the enemy within. J Alzheimers Dis 2008; 13: 393-405.
116. Lin WR, Shang D, Itzhaki RF. Neurotrophic viruses and Alzheimer's Disease: Interaction of Herpes Simplex type-1 virus and apolipoprotein E in the etiology of the disease. Molec Chem Neuropathol 1996; 28: 135-141.
117. Itzhaki RF, Dobson CB, Lin WR, Wozniak MA. Association of HSV1 and apolipoprotein E-varepsiolon4 in Alzheimer's disease. J Neurovirol 2001; 7: 570-571.
118. Shipley SJ, Parkin ET, Itzhaki RF, Dobson CB. Herpes Simplex virus interferes with amyloid precursor protein processing. BMC Microbiol 2005(Aug 18); 5: 48.
119. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 2007; 429: 95-100.
120. Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF. Cytomegalovirus is present in a very high proportion of brains from vscular dementia patients. Neurobiol Dis 2002; 9: 82-87.
121. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapies. J Biomed Biotechnol 2006; 2006: 31372.
122. Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, Eckert A, Muller WE. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's diseases? Antioxid Redox Signal 2007; 9: 1659-1675.
123. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Müller WE. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol 2006; 41: 668-673.
124. Keil U, Hauptmann S, Bonert A, Scherping I, Eckert A, Müller WE. Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations. J Alzheimers Dis 2006; 9: 139-146.
125. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Svaaskan E, Czech C, Gotz J, Eckert A. Amyloid-beta and tau
126. synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106: 20057-20062.
127. Wolters EC, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transmiss 2006; 70(suppl 1); 309-319.
128. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res 2004; 318: 115-120.
129. Sulzer D. Multiple hit hypothesis for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007; 30: 244-250.
130. Puschmann A. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013; 19: 407-415.
131. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013; 28: 14-23.
132. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann New York Acad Sci 2003; 991: 1-14.
133. Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 2013; 532: 18-23.
134. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case control study in north-east Italy. Acta Neurol Scand 2002; 105: 77-82.
135. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994; 7: 548-558.
136. Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect 2005; 113: 1234-1238.
137. Stoessl AJ. Etiology of Parkinson's disease. Can J Nuerol Sci 1999; 26(suppl 2): S5-S12.
138. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003; 111: 1065-1073.
139. Vlajinac H, Dzoljic E, Maksimovic J, Marinkovic J, Sipetic S, Kostic V. Infections as a risk factor for Parkinson's disease: a case-control study. Intern J Neurosci 2013; 123: 329-332.
140. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurol 2006; 66(suppl 4): S24-S36, 2006.
141. Dobbs RJ, Dobbs SM, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB. Role of chronic infection and inflammation in the gastroinstestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005; 10: 267-275.
142. Pierantozzi M, Piertroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci 2001; 22: 89-91.
143. Pierantozzi M, Piertroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernadi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurol 2006; 66: 1824-1829.
144. Barker RA, Cahn AP. Parkinson's disease: an autoimmune process. Intern J Neurosci 1988; 43: 1-7.
145. Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinson's disease. Histol Histopathol 2006; 21: 673-678.
146. Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson's disease. Curr Med Chem 2006; 13: 591-602.
147. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005; 193: 279-290.
148. Ogata A, Tashiro K, Nukuzuma S, Nagashima K, Hall WW. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurovirol 1997; 3: 141-147.
149. Beaman BL, Canfield D, Anderson J, Pate B, Calne D. Site-specific invasion of the basal ganglia by Nocaardia asteriodes GUH-2. Med Microbiol Immunol 2000; 188: 161-168.
150. De Chiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, Palamara AT. Infectious agents and neurodegeneration. Mol Neurobiol 2012; 46: 614-638.
151. Cassarino DS, Quezado MM, Ghatak NR, Duray PH. Lyme-associated parkinsonism: a neuropathologic case study and review of the literature. Arch pathol Lab Med 2003; 127: 1204-1206.
152. Ickenstein GW, Klotz JM, Langohr HD. Virus encepthalitis with symptomatic Parkinson syndrome, diabetes insipidus and panhypopituitarism. Fortschr Neurol Psychiat 1999; 67: 476-481.
153. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Movment Disord 1992; 7: 153-158.
154. Kim JS, Choi IS, Lee MC. Reversible parkinsonism and dystonia following Mycoplasma pneumoniae infection. Mov Disord 1995; 10: 510-512.
155. Maggi P, de Mari M, Moramarco A, Fiorentino G, Lamberti P, Angarano G. Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions. Neurol Sci 2000; 21: 173-176.
156. Mattson MP. Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 2004; 3: 105-120.
157. Alasia DD, Asekomeh GA, Unachuku CN. Parkinsonism induced by sepsis: a case report. Niger J Med 2006; 15: 333-336.
158. Onyango IG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res 2008; 33: 589-597.
159. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005; 14: 2749-2755.
160. Matsuda S, Kitagishi Y, Kobayashi M. Function and characteristics of PINK1 in mitochondria. Oxid Med Cell Longev 2013; 2013: 601587. doi: 10.1155/2013/601587. [Epub before print].
161. Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid Redox Signal 2011; 14: 1929-1938.
162. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010; 189: 211-221.
163. Johnson NL, Rodriguez D. Children with autism spectrum disorder at a pediatric hospital: a systematic review of the literature. Pediatr Nurs 2013; 39: 131-141.
164. Zwaigenbaum L, Bryson S, Garon N. Early identification of autism spectrum disorders. Behav Brain Res 2013; 251: 133-146.
165. Persico AM, Napolioni V. Autism genetics. Behav Brain Res 2013; 251: 95-112.
166. Zafeiriou DI, Ververi A, Dafoulis V, Kayyva E, Vargiami E. Autism spectrum disorders: the quest for genetic syndromes. Am J Med Genet Neuropsychiatr Genet 2013; 162B: 327-366.
167. Rimland B. The Autism epidemic, vaccinations and mercury. J Nut Environ Med 2000; 10: 261-266.
168. Downing D. Mercury again. J Nut Environ Med 2000; 10: 267-269.
169. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010; 23: 103-110.
170. Bransfield RC, Wulfman JS, Harvey WT, Usman AI. The association between tickbourne infections, Lyme borreliosis and autism spectrum disorders. Med Hypotheses 2008; 70: 967-974.
171. Zahir FR, Brown CJ. Epigenetic impacts on neurodevelopment: pathophysiological mechanisms and genetic modes of action. Pediatr Res 2011; 69: 92R-100R.
172. Gadad BS, Hewitson L, Young KA, German DC. Neuropathology and animal models of autism: genetic and environmental factors. Autism Res Treat 2013; 2013: 731935 [Epub Sept 16, 2013].
173. Takahashi H, Arai S, Tanaka-Taya K, et al. Autism and infection/immunization episodes in Japan. Jap J Infect Dis 2001; 54: 78-79
174. Libbey JE, Sweeten TL, McMahon WM, et al. Autistic disorder and viral infections. J Neurovirol 2005; 11: 1-10.
175. Bransfield RC, Kuhn M. Autism and Lyme disease. JAMA 2013; 310: 856-857.
176. Thornton D. A survey of Mycoplasma detection in veterinary vaccines. Vaccine 1986; 4: 237-240.
177. Nicolson GL, Nicolson NL. Diagnosis and treatment of mycoplasmal infections in Persian Gulf War Illness-CFIDS patients. Intern J Occupat Med Immunol Tox 1996; 5: 69-78.
178. Nicolson GL, Nasralla M, Nicolson NL, Haier J. High prevalence of mycoplasmal infections in symptomatic (Chronic Fatigue Syndrome) family members of mycoplasma-positive Gulf War Illness patients. J Chronic Fatigue Syndr 2003; 11(2): 21-36.
179. Nicolson GL, Berns P, Gan R, Haier J. Chronic mycoplasmal infections in Gulf War veterans' children and autism patients. Med Veritas 2005; 2: 383-387.
180. Bransfield RC, Wulfman JS, Harvey WT, Usman AI. The association between tick-borne infections, Lyme borreliosis and autism spectrum disorders. Med Hypotheses 2008; 70: 967-974.
181. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011; 59: 41R-47R.
182. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-anlaysis. Mol Psychiatry 2012; 17: 290-314.
183. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389-401.
184. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta 2010; 1797: 1130-1137.
185. McDonald E, David AS, Pelosi AJ, Mann AH. Chronic fatigue in primary care attendees. Psycholog Med 1993; 23: 987-998.
186. Morrison JD. Fatigue as a presenting complaint in family practice. J Family Pract 1980; 10: 795-801.
187. Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 1988; 260: 929-934.
188. Fukuda K, Strauss SE, Hickie I, Sharpe MC, Dobbines JG, Komaroff A. The Chronic Fatigue Syndrome, a comprehensive approach to its definition and study. Ann Internal Med 1994; 121: 953-959.
189. Crothers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles ACP, Sherkey JA, van de Sande MI. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr 2003; 11(1): 7-116.
190. Fletcher MA, Maher KJ, Klimas NG. Natural Killer cell function in chronic fatigue syndrome. Clin Appl Immunol Rev 2002; 2: 129-139.
191. Nijs J, Fremont M. Intercellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications. Expert Opin Ther Targets 2008; 12: 281-289.
192. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamo-pituitaryadrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007; 10: 13-25.
193. Patarca R. Cytokines and chronic fatigue syndrome. Ann New York Acad Sci 2001; 933: 185-200.
194. Silverman MN, Heim CM, Nater UM, Marques AH, Sternberg EM. Neuroendocrine and immune contributors to fatigue. PMR 2010; 2: 338-346.
195. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009; 8: 287-291.
196. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain Behav Immun 2012; 26: 1202-1210.
197. Nicolson GL, Nasralla M, Franco AR, Nicolson NL, Erwin R, Ngwenya R, Berns PA. Diagnosis and integrative treatment of intracellular bacterial infections in chronic fatigue and fibromyalgia syndromes, Gulf War illness, rheumatoid arthritis and other chronic illnesses. Clin Pract Alt Med 2000; 1(2): 92-102.
198. Nicolson, G.L., Nasralla, M., Gan, R., Haier, J. and De Meirleir, K. Evidence for bacterial (Mycoplasma, Chlamydia) and viral (HHV-6) co-infections in chronic fatigue syndrome patients. J Chronic Fatigue Syndr 2003; 11(2): 7-20.
199. Zhang L, Gough J, Christmas D, Mattey DL, Richards SC, Main J, Enlander D, Honeybourne D, Ayres JG, Nutt DJ, Kerr JR. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encepthalomyelitis. J Clin Pathol 2010; 63: 156-164.
200. Komaroff AL, Cho TA. Role of infection and neurologic dysfunction in chronic fatgue syndrome. Semin Neurol 2011; 31: 325-337.
201. Vojdani A, Choppa PC, Tagle C, Andrin R, Samimi B, Lapp CE. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol 1998; 22: 355-365.
202. Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 2003; 111: 557-566.
203. Vernon SD, Shukia SK, Reeves WC. Absence of Mycoplasma species DNA in chronic fatigue syndrome. J Med Microbiol 2003; 52: 1027-1028.
204. Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K. High prevalence of mycoplasmal infections among European Chronic Fatigue Syndrome patients. Examination of four Mycoplasma species in Chronic Fatigue Syndrome patients. FEMS Immunol Med Microbiol 2002; 34: 209-214.
205. Nicolson GL, Nicolson NL, Haier J. Chronic Fatigue Syndrome patients subsequently diagnosed with Lyme Disease Borrelia burgdorferi: evidence for Mycoplasma species co-infections. J Chronic Fatigue Syndr 2008; 15(4): 5-17.
206. Chia JKS, Chia LY. Chronic Chlamydia pneumoniae infection: a treatable cause of Chronic Fatigue Syndrome. Clin Infect Dis 1999; 29: 452-453.
207. Beqaj SH, Lerner AM, Fitzheerald JT. Immunossay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol 2008; 61: 623-526.
208. Seishima M, Mizutani Y, Shibuya Y, Arakawa C. Chronic fatigue syndrome after human parvovirus B19 infection without persistent viremia. Dermatol 2008; 216: 341-346.
209. Wagner M, Krueger GRF, Ablashi DV, Whitman JE. Chronic fatigue syndrome (CFS): a critical evaluation of testing for active human herpesvirus-6 (HHV-6) infection: a review of data on 107 cases. J Chronic Fatigue Syndr 1996; 5: 3-16.
210. Delviks-Frankenberry K, Cingöz O, Coffin JM, Pathak VK. Recombinant orgin, contamination and de-discovery of XMRV. Curr Opin Virol 2012; 2: 499-507.
211. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Intern J Clin Exp Med 2009; 2(1): 1-16.
212. Booth ME, Myhill S, McLaren-Howard J. Mitochonrial dysfunction and the pathophysiology of myalgic ecephalomyelitis/chronic fatigue syndrome (ME/CFS). Intern J Clin Exp Med 2012; 5: 208-220.
213. Agadjanyan M, Vasilevko V, Ghochikyan A, Berns P, Kesslak P, Settineri R, Nicolson GL. Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 2003; 11(3): 23-26.
214. Myhill S, Booth NE, McLaren-Howard J. Targeting mitochondrial dysfunction in the treatment of myalgic encepthalomyelitis/chronic fatigue syndrome (ME/CFS)-a clinical audit. Intern J Clin Exp Med 2013; 6(1): 1-15.
215. Rehm SE, Koroschetz J, Gockel U, Brosz M, Freynhagen R, Tölle TR, Baron R. A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatol 2010; 49: 1146-1152.
216. Breeding PC, Russell NC, Nicolson GL. An integrative model of chronically activated immune-hormonal pathways important in the generation of fibromyalgia. Brit J Med Practit 2012; 5(3): a524-a534.
217. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MD, Starck LO, Keck PE Jr. Family study of fibromyalgia. Arthritis Rheum 2004; 50: 944-952.
218. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003; 7(5): 362-368.
219. Bazzichi L, Rossi A, Giuliano T, De Feo F, Giacomelli C, Consensi A, Ciapparelli A, Consoli G, Dellosso L, Bombardieri S. Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 2007; 26: 2115-2120.
220. Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol 2004; 31: 2036-2040.
221. Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinol 1992; 17(6): 593-598.
222. Cordero MD, de Miguel M, Carmona-López I, Bonal P, Campa F, Moreno-Fernández AM. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett 2010; 31: 169-173.
223. Codero MD, De Miguel M, Moreno Fernández AM, Carmona López IM, Carrido Maraver J, Cotán D, Gómez Izquierdo L, Bonal P, Campa F, Bullon P, Navas P, Sánchez Alcázar JA. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010; 12(1): R17 [Jan 28, 2010 Epub].
224. Castro-Marrero J, Cordero MD, Sáez-Francas N, Jimenez-Gutierrez C, Aguilar-Montilla FJ, Aliste L, Alegre-Martin J. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal 2013; May 29 [Epub ahead of print].
225. Twig G, Shirihi OS. The interplay between mitochondrial dynamics and mitophagy. Antiox Redox Signal 2011; 14: 1939-1951.
226. Rich PR, Marechal A. The mitochondrial respiratory chain. Essays Biochem 2010; 47: 1-23.
227. Nicholls DG. Mitochondrial ion circuits. Essays Biochem 2010; 47: 25-35.
228. Richter C, Par JW, Ames B. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Nat Acad Sci USA 1998; 85: 6465-6467.
229. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Mitochondrial dysfunction in brain aging: role of oxidative stress and cardiolipin. Neurochem Intern 2011; 58: 447-457.
230. Stadtman E. Introduction to serial reviews on oxidatively modified proteins in aging and disease. Free Radical Biol Med 2002; 32: 789.
231. Duchen MR, Szabadkai G. Roles of mitochondria in human disease. Essays Biochem 2010; 47: 115-137.
232. Divakaruni AS, Brand MD. The regulation and physiology of mitochondrial proton leak. Physiology 2011; 26: 192-205.
233. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007; 292: C33-C44.
234. Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial mechanisms. Cell Molec Life Sci 2008; 65: 2493-2506.
235. Barber DA, Harris SR. Oxygen free radicals and antioxidants: a review. Am Pharmacol 1994; 34: 26-35
236. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radical Biol Med 1990; 8: 583-599.
237. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 1995; 64: 97-112.
238. Marí M, Morales A, Colell A, Garcia-Ruiz C, Kaplowitz N, Fernández-Checa JC. Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta 2013; 1830: 3317-3328.
239. Diplock AT, Charleux JL, Crozier-Willi G, Kok FJ, Rice-Evans C, Roberfroid M, Stahl W, Viña-Ribes J. Functional food science and defence against reactive oxidation species. Br J Nutr 1998; 80(Suppl 1): S77-S112.
240. Albarracin SL, Stab B, Casas Z, Sutachan JJ, Samudio I, Gonzalez J, Gonzalo L, Capani F, Morales L, Bareto GE. Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 2012; 15: 1-9.
241. Maarchal J, Pifferi F, Aujard F. Reservatrol in mammals: effects on aging biomarkers, age-related diseases and life span. Ann N Y Acad Sci 2013; 1290: 67-73.
242. Obrenovich ME, Li Y, Parvathaneni K, Yendluri BB, Palacios HH, Leszek J, Aliev G. Antioxidants in health, disease and aging. CNS Neurol Discord Drug Targets 2011; 10: 192-207.
243. DiMauro S, Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 2009; 1792: 1159-1167.
244. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genetics Metabol 2010; 99: 246-255.
245. Nicolson GL, Ash ME. Lipid Replacement Therapy: a natural medicine approach to replacing damaged phospholipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta 2013; 1838: in press.
246. Chambers D, Bagnall A-M, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encepthalomyelitis: an updated systematic review. J Royal Soc Med 2006; 99: 506-520.
247. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012; 51: 553-572.
248. Marcovina SM, Sirtori C, Peracino A, Gheorghiade M, Borum P, Remuzzi G, Ardehali H. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Translat Res 2012; Nov 5, pii: S1931-5244(12)00367-2. doi: 10.1016/j.trsl2012.10.006.
249. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
250. Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, Wenner BR, Dowdy ZE, Granger CB, Ginsburg GS, Newgard CB, Kraus WE. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 2009; 5: 258. doi:10.1038/msb.2009.11.
251. Spriet LL, Perrry CGR, Talanian JL. Legal pre-event nutritional supplements to assist energy metabolism. Essays Biochem 2008; 44: 27-43.
252. Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr 2000; 72; 618S-623S.
253. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995; 38: 201-210.
254. Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 12: 291-299.
255. Acetyl-L-Carnitine Monograph. Altern Med Rev 2010; 15(1): 76-83.
256. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. L-carnitine treatment reduces severity of physicial and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 2007; 86: 1738-1744.
257. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Medicinal Chem 2004; 11: 1135-1146.
258. Marczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Munch G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev 2008; 60: 1463-1470.
259. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009; 1790: 1149-1160.
260. Estrada DE, Ewart HS, Tsakiridis T, Volchuk A, ramtal T, Tritschler H, Klip A. Stimulation by alpha-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats. Life Sci 1997; 61: 805-812.
261. Gudz TI, Tserng KY, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997; 272: 24154-24158.
262. Di Paola M, Cocco T, Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria. Biochem. 2000; 39: 6660-6668.
263. Monette JS, Gomez LA, Moreau RF, Dunn KC, Butler JA, Finlay LA, Michels AJ, Shay KP, Smith EJ, Hagen TM. (R)- -Lipoic acid treatment restores ceramide balance in aging rat cardiac muscle. Pharmacol Res 2011; 63: 23-29.
264. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21: 114-121.
265. Ziegler D, Low PA, Litchy WJ, Boulton AJM, Vink AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus, J, Schute K, Dyck PJ. Efficacy and safety of antiox -Lipoic acid over 4 years in diabetic polyneuropathy. Diabetes Care 2011; 34: 2054-2060.
266. Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid-biological activity and therapeutic potential. Pharmacol Rep 2011; 63: 849-858.
267. Head E, Nukala VN, Fenoglio KA, Muggenburg BA, Cotman CW, Sullivan PG. Effects of age dietary and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp Neurol 2009; 220: 171-176.
268. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutr 2010; 26: 250-254.
269. Groneberg DA, Kindermann B, Althammer M, Klapper M, Vormann J, Littarru GP, Doring F. Coenzyme Q10 affects expression of genes involved in cell signaling, metabolism and transport in CaCo-2 cells. Intern J Biochem Cell Biol 2005; 37: 1208-1218.
270. Orsucci D, Mancuso M, Ienco EC, LoGerfo A, Siciliano G. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Medicinal Chem 2011; 18: 4053-4064.
271. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003; 18: 91-100.
272. Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T, Sugino T, Shirai T, Kajimoto Y, Kuratsune H, Kajimoto O, Watanabe Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutr 2008; 24: 293-299.
273. Li G, Jack CR, Yang XF, Yang ES. Diet supplement CoQ10 delays brain atrohy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors 2008; 32: 169-178
274. Yang X, Dai G, Li G, Yang ES. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PSI transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2010; 41: 110-113.
275. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cotrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer's disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69: 836-841.
276. Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrates that mitochondrial oxidative damage contributes to the neurodegenerative process. Neurosci Lett 2010; 220: 41-48.
277. Kieburtz K, Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurol 2001; 57: 397-404.
278. Thompson KP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66: 235-244.
279. Mathews PM, Ford B, Dandurand RJ, Eidelman DH, O'Connor D, Sherwin A, Karpati G, Andermann F, Arnold DL. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurol 1993; 43: 884-890.
280. Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharmaceut Design 2009; 15(1): 3-11.
281. Penberthy WT. Nicotinamide adenine dinucleotide biology and disease. Curr Pharmaceut Design 2009; 15(1): 1-2.
282. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996; 26(1): 1-9.
283. Swerdlow RH. Brain aging, Alzheimer's disease and mitochondria. Biochim Biophys Acta 2011; 1812: 1630-1639.
284. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolec Med 2008; 10: 291-315.
285. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009; 16: 4654-4667.
286. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011; 8: 393-409.
287. Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res 2004; 30(1):27-33.
288. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide-a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993; 146: 32-35.
289. Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson's disease with NADH. Acta Neurol Scand 1994; 90: 345-347.
290. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L jr, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999; 82: 185-191.
291. Colquhoun D, Senn S. Is NADH effective in the treatment of chronic fatigue syndrome? Ann Allergy Asthma Immunol 2000; 84: 639-640.
292. Santaella ML, Font I, Disdier OM. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. Puerto Rico Health Sci J 2004; 23: 89-93.
293. Alegre J, Rosés JM, Javierre C, Ruiz-Baqués A, Segundo MJ, de Sevilla TF. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Rev Clin España 2010; 210: 284-288.
294. Ellithorpe RR, Settineri R, Nicolson GL. Reduction of fatigue by use of a dietary supplement containing glycophospholipids. J Am Nutraceut Assoc 2003; 6(1): 23-28.
295. Nicolson GL, Ellithrope R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J Chronic Fatigue Syndr 2006; 13(1): 57-68.
296. Piper BF, Linsey AM, Dodd MJ. Fatigue mechanism in cancer. Oncol Nurs Forum 1987; 14: 17-23.
297. Nicolson GL, Ellithorpe RR, Ayson-Mitchell C, Jacques B, Settineri R. Lipid Replacement Therapy with a glycophospholipid-antioxidant-vitamin formulation significantly reduces fatigue within one week. J Am Nutraceutical Assoc 2010; 13(1): 10-14.
298. Kucharská J. Vitamins in mitochondrial function, in: Gvozdjáková A, ed. Mitochondrial Medicine, Springer, Netherlands, 2008, pp. 367-384.
299. Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. Mol Aspects Med 2005; 26: 363-378.
300. Scarpelli M, Cotelli MS, Mancuso M, Tomelleri G, Tonin P, Baronchelli C, Vielmi V, Gregorelli V, Todeschini A, Padovani A, Filosto M. Current options in the treatment of mitochondrial diseases. Recent Pat CNS Drug Discov 2010; 5: 203-209.
301. Ames BN. A role for supplements in optimizing health: the metabolic tune-up. Arch Biochem Biophys 2004; 423: 227-234.
302. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins, mitamins E and C, beta-carotene and other carotenoids. Ann N Y Acad Sci 1992; 669: 7-20.
303. Wojcik M, Burzynska-Pedziwiatr I, Wozniak LA. A review of natural and synthetic antioxidants important for health and longevity. Curr Med Chem 2010; 17: 3268-3288.
304. Huskisson E, Maggini S, Ruf M. Energy metabolism and well being. J Intern Med Res 2007; 35: 277-289.
305. Nicolson GL, Settineri R, Ellithorpe E. Lipid Replacement Therapy with a glycophospholipid formulation with NADH and CoQ10 significantly reduces fatigue in intractable chronic fatiguing illnesses and chronic Lyme disease. Intern J Clin Med 2012; 3(3): 163-170.
306. Perez-Pinzon MA, Stetler RA, Fiskum G. Novel mitochondrial targets for neuroprotection. J Cerebral Blood Flow Met 2012; 32: 1362-1376.
307. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signaling. Nat Rev Cell Mol Biol 2012; 13: 780-788.
308. Lartigue L, Faustin B. Mitochondria: metabolic regulators of innate immune responses to pathogens and cell stress. Intern J Biochem Cell Biol 2013; 45: 2052-2056.
309. Arnoult D, Soares F, Tattoli I, Girardin SE. Mitochondria in innate immunity. EMBO Rep 2011; 901-910.
310. Yuk J-M, Yoshimori T, Jo E-K, Autophagy and bacterial infectious disease. Exp Mol Med 2012; 44: 99-108.
311. Campoy E, Colombo MI. Autophagy in intracellular bacterial infection. Biochim Biophys Acta 2009; 1793: 1465-1477.
312. Orvedalh A, Levine B. Eating the enemy within: autophagy in infectious diseases. Cell Death Differ 2009; 16: 57-69.
313. Jo EK, Yang CS, Choi CH, Harding CV. Intracellular signaling cascades regulating innate immune responses to Mycobacteria: branchig out form Toll-like receptors. Cell Microbiol 2007; 9: 1087-1098.
314. Brodsky IE, Medzhitov R. Targeting of immune signaling networks by bacterial pathogens. Nat Cell Biol 2009; 11: 521-526.
315. Schroder K, J. Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
316. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
317. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, Vandenabeele P. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
318. Kryso DV, Vandenabeele P. Clearance of dead cells: mechanisms, immune responses and implication in the development of disease. Apoptosis 2010; 15: 995-997.
319. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
320. Tait SW, Green DR. Mitochondria and cell death: outer membrane permebilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632.
321. Ellithorpe RA, Settineri R, Jacques B, Nicolson GL. Lipid Replacement Therapy functional food with NT Factor for reducing weight, girth, body mass, appetite, cravings for foods and fatigue while improving blood lipid profiles. Funct Food Health Dis 2012; 2(1): 11-24.